Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

Genentech has kicked off a phase 2a clinical trial to optimize subretinal surgical delivery of OpRegen, a cell therapy that is in development as a treatment for the eye disease geographic atrophy.